BTAI

1.93

0.00% 0.00

Dopo l'orario di chiusura: 2.02 0.09 +4.66%

Bioxcel Therapeutics Inc (BTAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BTAI Giù? Forum Previsione

Precedente Chiudi:

$1.93

Aprire:

$1.98

Volume 24 ore:

78,653

Relative Volume:

0.27

Capitalizzazione di mercato:

$12.05M

Reddito:

$1.38M

Utile/perdita netta:

$-179.05M

Rapporto P/E:

-0.3143

EPS:

-6.14

Flusso di cassa netto:

$-155.03M

1 W Prestazione:

-4.93%

1M Prestazione:

+40.88%

6M Prestazione:

+366.18%

1 anno Prestazione:

+78.70%

Intervallo 1D:

$1.916

$1.98

Intervallo di 1 settimana:

$1.69

$2.08

Portata 52W:

$0.16

$6.83

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Nome

Bioxcel Therapeutics Inc

Settore

Healthcare (1160)

Industria

Biotechnology (651)

Telefono

203-643-8060

Indirizzo

555 LONG WHARF DRIVE, NEW HAVEN, CT

Dipendente

Cinguettio

@bioxcel_tx

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

BTAI's Discussions on Twitter

Confronta BTAI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BTAI Bioxcel Therapeutics Inc	1.93	12.05M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	459.62	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.36	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	331.91	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-21	Downgrade	UBS	Buy → Neutral
2023-08-15	Downgrade	Mizuho	Buy → Neutral
2023-07-17	Downgrade	Guggenheim	Buy → Neutral
2023-03-10	Downgrade	Jefferies	Buy → Hold
2022-12-01	Aggiornamento	Goldman	Sell → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-06	Reiterato	BofA Securities	Buy
2021-11-15	Downgrade	Goldman	Neutral → Sell
2021-04-09	Iniziato	Berenberg	Buy
2021-02-01	Iniziato	UBS	Buy
2020-10-30	Iniziato	Goldman	Buy
2020-09-02	Iniziato	Jefferies	Buy
2020-08-17	Reiterato	H.C. Wainwright	Buy
2020-07-08	Reiterato	H.C. Wainwright	Buy
2020-06-04	Iniziato	Guggenheim	Buy
2020-04-01	Iniziato	BofA/Merrill	Buy
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-12	Iniziato	SunTrust	Buy

Mostra tutto

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

Jun 16, 2025

BioXcel Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 16, 2025

May 30, 2025

Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent

May 30, 2025

BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa

May 30, 2025

May 29, 2025

BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia

May 29, 2025

SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 29, 2025

May 28, 2025

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN

May 28, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus

May 28, 2025

May 27, 2025

BTAIBioXcel Therapeutics Provides Clinical and Business Update - mx.advfn.com

May 27, 2025

BioXcel’s Phase 3 trial of BXCL501 continues as advised by DSMB - Investing.com India

May 27, 2025

BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq L - GuruFocus

May 27, 2025

BioXcel Therapeutics granted Nasdaq extension - Investing.com Australia

May 27, 2025

BioXcel granted an extension for compliance by Nasdaq - Hartford Business Journal

May 27, 2025

BioXcel Therapeutics granted Nasdaq extension By Investing.com - Investing.com South Africa

May 27, 2025

BTAI's Phase 3 Trial for BXCL501 Advances Unhindered by Safety Concerns | BTAI Stock News - GuruFocus

May 27, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated wit - GuruFocus

May 27, 2025

Bioxcel Therapeutics Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirement - marketscreener.com

May 27, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

May 27, 2025

BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq Listing - GuruFocus

May 27, 2025

BioXcel's Breakthrough At-Home Agitation Drug Clears Critical Safety Review, First FDA Approval Possible - Stock Titan

May 27, 2025

BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | B - GuruFocus

May 27, 2025

BioXcel Granted Nasdaq Compliance Extension Until September - TipRanks

May 27, 2025

BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | BTAI Stock News - GuruFocus

May 27, 2025

BioXcel Gets Critical Nasdaq Reprieve: 4-Month Extension as Phase 3 Trial Results Near - Stock Titan

May 27, 2025

May 26, 2025

BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN

May 26, 2025

May 24, 2025

Can a $10,000 Investment in SoundHound AI Turn Into $1 Million by 2035? - The Globe and Mail

May 24, 2025

May 18, 2025

BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail

May 18, 2025

May 14, 2025